Finance5 sources

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

  • Eli Lilly plans to buy Calytrix Bio for up to $1.5 billion.
  • The acquisition aims to bolster Eli Lilly's cancer and immunology business.
  • This deal is part of Eli Lilly's broader $32 billion acquisition spree in 2026.
  • Calytrix Bio specializes in developing treatments for rare blood cancers.
  • The acquisition is expected to enhance Eli Lilly's market position in oncology.

Timeline

  1. Lilly to buy Calytrix for up to $1.5 billion

    Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion.

  2. Lilly signs cancer research deal with Stipple Bio

    Lilly signs a cancer research deal with Stipple Bio worth up to $5.9 billion.

  3. Lilly Buying Spree Surpasses $32B

    Lilly's acquisition of Calytrix Bio is part of a $32 billion wave of acquisitions in 2026.

  4. Latest

    Lilly's Next Big Growth Opportunity

    Lilly's third-quarter update shows core growth drivers, including Mounjaro and Zepbound.

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion | Split Angle